Literature DB >> 10573151

Involvement of beta2-microglobulin and integrin alphavbeta3 molecules in the coxsackievirus A9 infectious cycle.

Martha Triantafilou1, Kathy Triantafilou1, Keith M Wilson1, Yoshikazu Takada2, Nelson Fernandez1, Glyn Stanway1.   

Abstract

It is becoming apparent that many viruses employ more than one cell surface molecule for their attachment and cell entry. In this study, we have tested the role of integrin alpha(v)beta3 and MHC class I molecules in the coxsackievirus A9 (CAV-9) infectious cycle. Binding experiments utilizing CHO cells transfected and expressing human integrin alpha(v)beta3, revealed that CAV-9 particles were able to bind to cells, but did not initiate a productive cell infection. Antibodies specific for integrin alpha(v)beta3 molecules significantly reduced CAV-9 infection in susceptible cell lines. Moreover, MAbs specific for beta2-microglobulin (beta2-m) and MHC class I molecules completely inhibited CAV-9 infection. To assess the effect of these antibodies on virus binding, we analysed CAV-9 binding by flow cytometry in the presence of alpha2-m- or integrin alpha(v)beta3-specific antibodies. The results showed a reduction in CAV-9 binding in the presence of integrin alpha(v)beta3-specific antibodies while there was no reduction in the presence of beta2-m-specific MAb. Taken together, these data suggest that integrin alphavbeta3 is required for CAV-9 attachment but is not sufficient for cell entry, while beta2-m, although not directly involved in CAV-9 binding, plays a post-attachment role in the CAV-9 infectious process, possibly being involved in virus entry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573151     DOI: 10.1099/0022-1317-80-10-2591

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Arginine-glycine-aspartic acid motif is critical for human parechovirus 1 entry.

Authors:  Y Boonyakiat; P J Hughes; F Ghazi; G Stanway
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells.

Authors:  A Reischl; M Reithmayer; G Winsauer; R Moser; I Gösler; D Blaas
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

4.  GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatibility complex class I molecules which mediate virus internalization.

Authors:  Kathy Triantafilou; Didier Fradelizi; Keith Wilson; Martha Triantafilou
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Entry of human parechovirus 1.

Authors:  P Joki-Korpela; V Marjomäki; C Krogerus; J Heino; T Hyypiä
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Analysis of foot-and-mouth disease virus internalization events in cultured cells.

Authors:  Vivian O'Donnell; Michael LaRocco; Hernando Duque; Barry Baxt
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  RGD tripeptide of bluetongue virus VP7 protein is responsible for core attachment to Culicoides cells.

Authors:  B H Tan; E Nason; N Staeuber; W Jiang; K Monastryrskaya; P Roy
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

8.  Internalization of coxsackievirus A9 is mediated by {beta}2-microglobulin, dynamin, and Arf6 but not by caveolin-1 or clathrin.

Authors:  Outi Heikkilä; Petri Susi; Tuire Tevaluoto; Heidi Härmä; Varpu Marjomäki; Timo Hyypiä; Saija Kiljunen
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Coxsackievirus A9 infects cells via nonacidic multivesicular bodies.

Authors:  Moona Huttunen; Matti Waris; Ritva Kajander; Timo Hyypiä; Varpu Marjomäki
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

10.  Coxsackievirus B4-induced cytokine production in pancreatic cells is mediated through toll-like receptor 4.

Authors:  Kathy Triantafilou; Martha Triantafilou
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.